Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Diffuse Large B-cell Lymphoma(DLBCL)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT07538180
What this trial is testing

Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL

Who this might be right for
Newly Diagnosed MYC/BCL2 Double-expressor DLBCL
Sun Yat-sen University 30
Testing effectiveness (Phase 2)Study completedNCT02445248
What this trial is testing

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Who this might be right for
Diffuse Large B-cell Lymphoma (DLBCL)
Novartis Pharmaceuticals 115
Not applicableStudy completedNCT07181785
What this trial is testing

Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.

Who this might be right for
Diffuse Large B Cell Lymphoma (DLBCL)
Andrés José Maria Ferreri 555
Very early researchStudy completedNCT02405078
What this trial is testing

Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center 35
Testing effectiveness (Phase 2)WithdrawnNCT04285268
What this trial is testing

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell Lymphoma+4 more
Rutgers, The State University of New Jersey
Early research (Phase 1)Ended earlyNCT02978235
What this trial is testing

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Who this might be right for
Multiple MyelomaNonHodgkin Lymphoma
Taiho Oncology, Inc. 11
Large-scale testing (Phase 3)UnknownNCT05054426
What this trial is testing

Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL

Who this might be right for
Diffuse Large B Cell LymphomaCentral Nervous System Lymphoma
Peking Union Medical College Hospital 488
Testing effectiveness (Phase 2)UnknownNCT02758925
What this trial is testing

CyBeR Association in Relapsed/Refractory DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
University Hospital, Caen 78
Early research (Phase 1)Looking for participantsNCT05544019
What this trial is testing

Study of SGR-1505 in Mature B-Cell Neoplasms

Who this might be right for
Mature B-Cell NeoplasmNon Hodgkin LymphomaDLBCL+23 more
Schrödinger, Inc. 98
Testing effectiveness (Phase 2)Active Not RecruitingNCT03162536
What this trial is testing

Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Who this might be right for
Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia+6 more
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 190
Testing effectiveness (Phase 2)Looking for participantsNCT05326243
What this trial is testing

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaPrimary Mediastinal Large B Cell LymphomaLarge B-cell Lymphoma+2 more
Pell Bio-Med Technology Co., Ltd. 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT03960840
What this trial is testing

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaDiffuse Large B-cell Lymphoma+2 more
Novartis Pharmaceuticals 217
Testing effectiveness (Phase 2)Looking for participantsNCT05826535
What this trial is testing

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Who this might be right for
Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon-Hodgkin Lymphoma+1 more
Lyell Immunopharma, Inc. 270
Testing effectiveness (Phase 2)UnknownNCT02542111
What this trial is testing

Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL

Who this might be right for
Diffuse Large B-cell Lymphoma
Ruijin Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT07365306
What this trial is testing

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Primary Mediastinal Large B-Cell Lymphoma+5 more
City of Hope Medical Center
Testing effectiveness (Phase 2)Looking for participantsNCT06375733
What this trial is testing

GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

Who this might be right for
Large B-cell Lymphoma
Genfleet Therapeutics (Shanghai) Inc. 51
Testing effectiveness (Phase 2)Active Not RecruitingNCT05192486
What this trial is testing

GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd. 12
Early research (Phase 1)Study completedNCT02431988
What this trial is testing

Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation

Who this might be right for
Diffuse Large B-Cell Lymphoma
University College, London 10
Testing effectiveness (Phase 2)Looking for participantsNCT06854159
What this trial is testing

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma+1 more
University of California, Davis 34
Early research (Phase 1)Study completedNCT02417285
What this trial is testing

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Who this might be right for
Lymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
Celgene 75
Next Page
43